LBH589 Treatment for Refractory Clear Cell Renal Carcinoma
- First Posted Date
- 2007-10-29
- Last Posted Date
- 2021-11-23
- Lead Sponsor
- SCRI Development Innovations, LLC
- Target Recruit Count
- 20
- Registration Number
- NCT00550277
- Locations
- 🇺🇸
Peninsula Cancer Institute, Newport News, Virginia, United States
🇺🇸Northeast Georgia Medical Center, Gainesville, Georgia, United States
🇺🇸Tennessee Oncology, PLLC, Nashville, Tennessee, United States
Vinflunine in Hormone Refractory Prostate Cancer (HRPC)
- First Posted Date
- 2007-10-17
- Last Posted Date
- 2021-12-16
- Lead Sponsor
- SCRI Development Innovations, LLC
- Target Recruit Count
- 41
- Registration Number
- NCT00545766
- Locations
- 🇺🇸
Tennessee Oncology, PLLC, Nashville, Tennessee, United States
🇺🇸Florida Cancer Specialists, Fort Myers, Florida, United States
🇺🇸Chattanooga Oncology Hematology Associates, Chattanooga, Tennessee, United States
Adjuvant Doxorubicin/Cyclophosphamide and Paclitaxel Plus Sorafenib Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2007-10-16
- Last Posted Date
- 2013-04-01
- Lead Sponsor
- SCRI Development Innovations, LLC
- Target Recruit Count
- 45
- Registration Number
- NCT00544167
- Locations
- 🇺🇸
Chattanooga Oncology Hematology Associates, Chattanooga, Tennessee, United States
🇺🇸Integrated Community Oncology Network, Jacksonville, Florida, United States
🇺🇸Consultants in Blood Disorders and Cancer, Louisville, Kentucky, United States
Radiation Therapy and Temozolomide Followed by Temozolomide Plus Sorafenib for Glioblastoma Multiforme
- Conditions
- Interventions
- First Posted Date
- 2007-10-16
- Last Posted Date
- 2016-09-01
- Lead Sponsor
- SCRI Development Innovations, LLC
- Target Recruit Count
- 47
- Registration Number
- NCT00544817
- Locations
- 🇺🇸
Spartanburg Regional Medical Center, Spartanburg, South Carolina, United States
🇺🇸Methodist Cancer Center, Omaha, Nebraska, United States
🇺🇸Tennessee Oncology, Nashville, Tennessee, United States
CC-4047 With Gemcitabine for Untreated Advanced Carcinoma of the Pancreas
- First Posted Date
- 2007-10-08
- Last Posted Date
- 2013-03-13
- Lead Sponsor
- SCRI Development Innovations, LLC
- Target Recruit Count
- 23
- Registration Number
- NCT00540579
- Locations
- 🇺🇸
University of Colorado Cancer Center, Aurora, Colorado, United States
🇺🇸Tennessee Oncology, PLLC, Nashville, Tennessee, United States
Sorafenib and Bortezomib Treatment for Relapsed or Refractory Multiple Myeloma Patients
- First Posted Date
- 2007-09-28
- Last Posted Date
- 2013-02-27
- Lead Sponsor
- SCRI Development Innovations, LLC
- Target Recruit Count
- 13
- Registration Number
- NCT00536575
- Locations
- 🇺🇸
Center for Cancer and Blood Disorders, Bethesda, Maryland, United States
🇺🇸Tennessee Oncology, PLLC, Nashville, Tennessee, United States
Fludarabine, Rituximab, and Lenalidomide in Minimally Treated/Untreated Patients With Chronic Lymphocytic Leukemia (CLL)
- Conditions
- Interventions
- First Posted Date
- 2007-09-27
- Last Posted Date
- 2017-01-16
- Lead Sponsor
- SCRI Development Innovations, LLC
- Target Recruit Count
- 64
- Registration Number
- NCT00536341
- Locations
- 🇺🇸
Florida Cancer Specialists, Fort Myers, Florida, United States
🇺🇸National Capital Clinical Research Consortium, Bethesda, Maryland, United States
🇺🇸Center for Cancer and Blood Disorders, Bethesda, Maryland, United States
First-Line Treatment of A Comparison of 2 Treatments in Elderly Patients With Advanced NSCLC
- Conditions
- Interventions
- First Posted Date
- 2007-04-04
- Last Posted Date
- 2022-05-03
- Lead Sponsor
- SCRI Development Innovations, LLC
- Target Recruit Count
- 110
- Registration Number
- NCT00456261
- Locations
- 🇺🇸
Northeast Alabama Regional Medical Center, Anniston, Alabama, United States
🇺🇸Grand Rapids Clinical Oncology Program, Grand Rapids, Michigan, United States
🇺🇸NEA Baptist Clinic, Jonesboro, Arkansas, United States
High-dose Bevacizumab in Advanced Renal Carcinoma Patients
- First Posted Date
- 2007-04-04
- Last Posted Date
- 2014-12-22
- Lead Sponsor
- SCRI Development Innovations, LLC
- Target Recruit Count
- 119
- Registration Number
- NCT00455975
- Locations
- 🇺🇸
Tennessee Oncology, PLLC, Nashville, Tennessee, United States
🇺🇸Florida Cancer Specialists, Fort Myers, Florida, United States
🇺🇸Northeast Georgia Medical Center, Gainesville, Georgia, United States
Bevacizumab Given With Either Anastrozole or Fulvestrant With Trastuzumab for Postmenopausal Metastatic Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2006-11-30
- Last Posted Date
- 2021-11-18
- Lead Sponsor
- SCRI Development Innovations, LLC
- Target Recruit Count
- 79
- Registration Number
- NCT00405938
- Locations
- 🇺🇸
Sletten Cancer Institute, Great Falls, Montana, United States
🇺🇸Tennessee Oncology, PLLC, Nashville, Tennessee, United States
🇺🇸Florida Cancer Specialists, Fort Myers, Florida, United States